Johnson & Johnson (JNJ), Monday announced new data regarding IMAAVY, an FcRn blocker, in adults with generalized myasthenia gravis or gMG.
The data, taken from an indirect treatment comparison, which included the pivotal Phase 3 Vivacity-MG3 study data, revealed that IMAAVY showed comparable onset of symptom relief at Week 1 and showed consistent and sustained disease control with greater or statistically significant improvement of MG-ADL scores.
Vice President Katie Abouzahr stated that the analysis highlighted IMAAVY's potential as a reliable treatment option for appropriate patients aged 12 and older living with gMG.
Notably, IMAAVY received U.S. FDA approval earlier this year for the broadest population of individuals living with gMG, including anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older.
Currently, JNJ is trading at $150.74, up 0.63 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.